Testicular cancer from diagnosis to epigenetic factors
- PMID: 29262668
- PMCID: PMC5732834
- DOI: 10.18632/oncotarget.20992
Testicular cancer from diagnosis to epigenetic factors
Abstract
Testicular cancer (TC) is one of the most common neoplasms that occurs in male and includes germ cell tumors (GCT), sex cord-gonadal stromal tumors and secondary testicular tumors. Diagnosis of TC involves the evaluation of serum tumor markers alpha-fetoprotein, human chorionic gonadotropin and lactate dehydrogenase, but clinically several types of immunohistochemical markers are more useful and more sensitive in GCT, but not in teratoma. These new biomarkers are genes expressed in primordial germ cells/gonocytes and embryonic pluripotency-related cells but not in normal adult germ cells and they include PLAP, OCT3/4 (POU5F1), NANOG, SOX2, REX1, AP-2γ (TFAP2C) and LIN28. Gene expression in GCT is regulated, at least in part, by DNA and histone modifications, and the epigenetic profile of these tumours is characterised by genome-wide demethylation. There are different epigenetic modifications in TG-subtypes that reflect the normal developmental switch in primordial germ cells from an under- to normally methylated genome. The main purpose of this review is to illustrate the findings of recent investigations in the classification of male genital organs, the discoveries in the use of prognostic and diagnostic markers and the epigenetic aberrations mainly affecting the patterns of DNA methylation/histone modifications of genes (especially tumor suppressors) and microRNAs (miRNAs).
Keywords: biomarkers; epigenetic factors; germ cell neoplasia; seminoma; testicular cancer.
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
References
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. - PubMed
-
- Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in TC incidence and mortality. Eur Urol. 2011;60:374–9. - PubMed
-
- Jones RH, Vasey PA. Part II: testicular cancer--management of advanced disease. Lancet Oncol. 2003;4:738–47. - PubMed
-
- Rajpert-De Meyts E, Skakkebaek NE. Pathogenesis of testicular carcinoma in situ and germ cell cancer: still more questions than answers. Int J Androl. 2011;34:e2–6. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
